ViiV files HIV combo pill Trii in EU
This article was originally published in Scrip
Executive Summary
Viiv Healthcare has submitted a marketing authorization application in Europe for its single-tablet regimen of dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) – referred to as Trii – as a treatment for HIV-1 infection.